Jump to content

  • Set Your Location
  • Sign in or Enroll
Set Your LocationEden Medical Center
  • Sign in or Enroll
    • Open I want to choose my medical group or hospital
    • Clear my location
Change Location
Sutter Health
  • Video Visits
  • Find Doctors
  • Find Locations
  • Treatments & Services
    • Video Visits
    • Find Doctors
    • Find Locations
    • Treatments & Services
    • COVID-19 Resources
    • Pay a Bill
    • Symptom Checker
    • Get Care Today
    • Health & Wellness
    • Classes & Events
    • Research & Clinical Trials
    • For Patients
    • About Sutter Health
    • Giving
    • Volunteering
    • Careers
    • News
    • For Medical Professionals
    • Other Business Services
Close Search
  • Home
  • Eden
  • Research
  • Women's Health
Content

The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.

Description

Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PB., J Am Coll Cardiol. 54(21):1935-45. doi: 10.1016/j.jacc.2009.05.074. , 2009 Nov 17

Investigators

J.B. Jones, PhD, MBA

Abstract

OBJECTIVES: This study sought to investigate the efficacy and safety of clopidogrel in women and men.

BACKGROUND: Previous analyses have shown sex-based differences in response to several antiplatelet medications. Little is known about the efficacy and safety of clopidogrel in women and men.

METHODS: This study performed a meta-analysis of all blinded randomized clinical trials comparing clopidogrel and placebo (CURE [Clopidogrel in Unstable Angina to Prevent Recurrent Events], CREDO [Clopidogrel for the Reduction of Events During Observation], CLARITY-TIMI 28 [Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis In Myocardial Infarction 28], COMMIT [Clopidogrel and Metoprolol in Myocardial Infarction Trial], and CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance] trials), involving a total of 79,613 patients, of whom 30% were women. The relative efficacy and safety of clopidogrel at reducing cardiovascular events (cardiovascular death, myocardial infarction [MI], or stroke) in women and men was estimated using random-effects modeling.

RESULTS: Overall, clopidogrel was associated with a highly significant 14% proportional reduction in the risk of cardiovascular events (odds ratio [OR]: 0.86; 95% confidence interval [CI]: 0.80 to 0.93), with no significant differences in treatment effect between women and men. Among the 23,533 women enrolled, there were fewer cardiovascular events in the clopidogrel group compared with the placebo group (11.0% vs. 11.8%; OR: 0.93; 95% CI: 0.86 to 1.01). In women the risk reduction with clopidogrel seemed to be greatest for MI (OR: 0.81; 95% CI: 0.70 to 0.93), with the effects on stroke (OR: 0.91; 95% CI: 0.69 to 1.21) or total death (OR: 0.99; 95% CI: 0.90 to 1.08) not statistically significant. Among the 56,091 men enrolled, there were fewer cardiovascular events in those receiving clopidogrel compared with placebo (7.8% vs. 9.0%; OR: 0.84; 95% CI: 0.78 to 0.91), and the risk reduction was significant for MI (OR: 0.83; 95% CI: 0.76 to 0.92), stroke (OR: 0.83; 95% CI: 0.71 to 0.96), and total death (OR: 0.91; 95% CI: 0.84 to 0.97). Clopidogrel increased the risk of major bleeding in both women (OR: 1.43; 95% CI: 1.15 to 1.79) and men (OR: 1.22; 95% CI: 1.05 to 1.42).

CONCLUSIONS: Clopidogrel reduces the risk of cardiovascular events in both women and men.

Pubmed Abstract

Pubmed AbstractOpens New Window

Associated Topics

  • Cardiovascular Diseases
  • Cerebrovascular Disorders
  • Men's Health
  • Women's Health

Related Publications

Physicians’ well-being linked to in-basket messages generated by algorithms In EHRs.

Tai-Seale M, Dillon EC, Yang Y, Nordgren R, Steinberg R, Nauenberg T, Lee TC, Meehan A, Li J, Chan AS, Frosch D.
Health Aff. 38(7): https://doi.org/10.1377/hlthaff.2018.05509.
2019 Jul 01

Physicians’ well-being linked to in-basket messages generated by algorithms In electronic health records.

Tai-Seale M, Dillon EC, Yang Y, Nordgren R, Steinberg R, Nauenberg T, Lee TC, Meehan A, Li J, Chan AS, Frosch D.
Health Aff. 38(7): https://doi.org/10.1377/hlthaff.2018.05509.
2019 Jul 01

Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.

Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J.
Obstet Gynecol. 111(5):1175-82. doi: 10.1097/AOG.0b013e31816fd73b.
2008 May 01

Breast cancer chemoprevention in primary care - assessing readiness for change.

Wang H, Snyder CF, Larson S, Vogel V, Kirchner HL, Sun H, Yan X. 24(6):283-288.
Qual Prim Care.
2016 Nov 01

Does transition of urinary incontinence from one subtype to another represent progression of the disease?

Minassian VA, Yan X, Pilzek AL, Platte R, Stewart WF.
Int Urogynecol J. 29(8):1179-1185. doi: 10.1007/s00192-018-3596-4. Epub 2018 Mar 13.
2018 Aug 01
The Sutter Health Network of Care
Expertise to fit your needs
Primary Care

Check-ups, screenings and sick visits for adults and children.

Specialty Care

Expertise and advanced technologies in all areas of medicine.

Emergency Care

For serious accidents, injuries and conditions that require immediate medical care.

Urgent Care

After-hours, weekend and holiday services.

Walk-In Care

Convenient walk-in care clinics for your non-urgent health needs.

  • Contact Us
  • Find Doctors
  • Find Locations
  • Request Medical Records
  • Make a Gift
Sign in to My Health Online

Billing and Insurance

  • Pay a Bill
  • Accepted Health Plans
  • Estimate Costs
  • Medicare Advantage

About Sutter

  • About Our Network
  • Community Benefit
  • Annual Report
  • News

Our Team

  • For Employees
  • For Medical Professionals
  • For Vendors
  • For Volunteers

Careers

  • Jobs at Sutter
  • Physician Jobs
  • Graduate Medical Education

Copyright © 2023 Sutter Health. All rights reserved. Sutter Health is a registered trademark of Sutter Health ®, Reg. U.S. Patent & Trademark office.

  • ADA Accessibility
  • Privacy
  • Do Not Sell My Personal Information
  • LinkedIn Opens new window
  • YouTube Opens new window
  • Facebook Opens new window
  • Twitter Opens new window
  • Instagram Opens new window
  • Glassdoor Opens new window

Cookie Policy

We use cookies to give you the best possible user experience. By continuing to use the site, you agree to the use of cookies. Privacy Policy Cookie Preferences

Privacy Policy Cookie Preferences